Ocular Therapeutix (OCUL) shares rose more than 12% in recent trading on Wednesday after the company said it will close enrollment this week in its registration trial evaluating Axpaxli for wet age-related macular degeneration.
Ocular said it expects to meet its target of randomizing at least 555 subjects in the trial, with participants enrolled across approximately 100 sites in the US, Argentina, India, and Australia.
The SOL-R trial is evaluating the safety and efficacy of Axpaxli dosed every six months versus aflibercept given every eight weeks, Ocular said.
The company said it plans to file a new drug application with the US Food and Drug Administration pending positive results from SOL-R and a separate registrational study, SOL-1.
Price: 7.80, Change: +0.86, Percent Change: +12.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.